November 2021: 5 Notable Drug Approvals
The new approvals include Besremi, Fyarro, Livtencity, Voxzogo, and Vuity.
Ophthalmic Disorders
Growing Evidence Links Pentosan Polysulfate Sodium, Maculopathy
Specific retinal conditions proportionately more common for PPS users versus users of other interstitial cystitis, bladder pain drugs
ACR: Risk Factors ID’d for Hydroxychloroquine-Related Retinopathy
Independent risk factors for HCQ retinopathy include higher doses, longer duration of use, chronic kidney disease, and Asian race
New Drug Product: Susvimo
This slideshow shows drug information for Susvimo. Click here for the complete Susvimo monograph.
MPR Weekly Dose Podcast Episode 99
This week on the pod, there’s positive news for the COVID-19 oral antiviral candidate, Paxlovid; The CDC expands a recall for aromatherapy sprays connected to fatal cases of a rare tropical disease; The first eye drop to treat presbyopia is approved; An alternative to naloxone gets fast tracked; And a study compares the migraine treatments erenumab and topiramate.
October 2021: 5 Notable Drug Approvals
Review the October 2021 notable drug approvals.
Tyrvaya Nasal Spray Now Available for Dry Eye Disease
Tyrvaya contains varenicline, a highly selective nicotinic acetylcholine agonist.
FDA Approves First Eye Drop to Treat Presbyopia
The approval was based on data from the phase 3 GEMINI 1 and GEMINI 2 studies that evaluated Vuity in a total of 750 patients aged 40 to 55 years with presbyopia.
MPR Weekly Dose Podcast Episode 98
FDA Advisory Committee votes on whether the Pfizer-BioNTech vaccine should be authorized in 5 to 11 year olds; The Moderna vaccine elicits strong antibody responses in pediatrics; Trial results shed light on booster dose efficacy; Shingrix is recommended for immunocompromised patients; A novel treatment is approved for macular edema associated with uveitis; And Pepaxto is withdrawn following new findings.
USPSTF: Evidence Lacking for Screening Seniors for Visual Acuity
Current evidence is insufficient for assessing the balance of benefits and harms of screening asymptomatic ≥65s in primary care setting
